[Table/Fig-5]:

Studies depicting effects of adalimumab in treatment of RAS.

STUDY	SUBJECTS	TREATMENT	EFFECTS
Kaji M et al., (2015) [45]	13-year-old girl presented with RAS due to BD.	Adalimumab was given subcutaneously (160 mg in week 0, 80 mg in week 2, and 40 mg every other week thereafter).	Resolution of the clinical manifestations and symptoms were observed shortly after the commencement of adalimumab.
Tanida S et al., (2015) [47]	Patients with Behcet’s disease.	160 mg adalimumab initially, followed by 80 mg after two weeks and 80 mg or 40 mg every alternate week for 52 weeks.	Two-thirds of patients with oral ulcers had a complete resolution at week 52.
Perra D et al., (2012) [48]	19 patients with BD of whom 8 had severe aphthous disease.	40 mg adalimumab was given every 2 weeks, except one patient who was given the drug every 3 weeks.	Complete remission was seen in five of the 8 patients (62.5%) who had severe aphthous disease, while the remaining three cases responded only partially.
Vujevich J et al., (2005) [49]	18-year-old man with a 7-year history of severe major aphthous stomatitis unresponsive to standard therapy.	Adalimumab	Good response